Conference
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.
Abstract
225
Background: Two phase III trials, COMET-1 and COMET-2, have reported that cabozantinib did not extend overall survival (OS) outcomes compared to prednisone and prednisone plus mitoxantrone respectively, in unselected post-docetaxel patients with mCRPC. We conducted a retrospective analysis of a combined dataset of these trials in an attempt to identify a benefit in subsets of patients based on prognostic risk factors. …
Authors
Pond GR; Sonpavde G; Fizazi K; De Bono JS; Basch EM; Scher HI; Smith MR
Volume
36
Pagination
pp. 225-225
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
February 20, 2018
DOI
10.1200/jco.2018.36.6_suppl.225
Conference proceedings
Journal of Clinical Oncology
Issue
6_suppl
ISSN
0732-183X